KZR-261

Overview

KZR-261 is a Sec61 translocase inhibitor. KZR-261 binds directly to the Sec61 channel, thereby inhibiting the biosynthesis of certain Sec61 substrate proteins, including oncogenic factors. KZR-261 activates the endoplasmic reticulum stress response. KZR-261 exhibits broad in vitro anticancer activity. KZR-261 shows antitumor efficacy in mouse models of cancer . KZR-261 can be used for the research of multiple myeloma, colorectal cancer , small cell lung cancer , pancreatic cancer , prostate cancer , non-Hodgkin's lymphoma, and mantle cell lymphoma.

Application

Products | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Small Cell Lung Cancer | Products > Disease Areas > Non-Hodgkin Lymphoma | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Lung Cancer | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Sec61

Product Information

• Catalog No.: HY-176763
• CAS No.: 2376747-46-3
• Molecular Formula: C38H61FN6O5S2
• Molecular Weight: 765.06
• Purity: 99.39%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (3.27 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source